Signals
14Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD
Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Sarcoidosis acquires mechanism-targeted therapy after a long quiet period
Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.
PAH combination therapy moves to first-line
Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.
Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Tezepelumab uptake in type-2-low severe asthma is the field's defining commercial test
Tezepelumab's upstream mechanism (anti-TSLP) reaches patients in the type-2-low phenotype that the downstream biologic class cannot effectively serve. Real-world commercial uptake in this previously underserved population is the test of whether the upstream-mechanism advantage translates from clinical evidence to commercial reality.
IPF antifibrotic class is evolving with second-generation mechanisms
Idiopathic pulmonary fibrosis treatment has been defined by the two approved antifibrotics (pirfenidone, nintedanib) for a decade. The second-generation pipeline is now reading out, with mechanisms targeting different points in the fibrotic pathway and the potential to combine with the established class.
COPD triple-therapy uptake remains uneven across markets
Single-inhaler triple therapy in COPD is the guideline-supported regimen for the eligible population, but real-world uptake remains uneven across major markets driven by step-therapy protocols, prescriber inertia, and access geography.
Severe asthma biologics: which patients are still being left out?
Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.
Snapshots
5Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Severe COPD therapy reference (2026)
Reference snapshot of severe COPD therapy across foundational inhaler, biologic, and emerging mechanism tiers.
Obstructive sleep apnea therapy reference (2026)
Reference snapshot of OSA therapy across positive airway pressure, oral appliances, surgery, neurostimulation, and emerging pharmacotherapy.
Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
COPD pipeline expansion, 2026 mid-year reference
Reference layout of the COPD therapeutic pipeline as of mid-2026: established inhaled bronchodilator and inhaled corticosteroid combinations, the emerging biologic class (anti-IL-5, anti-IL-33, anti-TSLP), novel small-molecule mechanisms, and the live commercial questions across the pipeline.
Explained
5What is allergic bronchopulmonary aspergillosis?
Plain-language primer on ABPA, why it is different from typical asthma, and how modern therapy works.
Severe COPD and biologic therapy explained
Plain-language primer on severe COPD, why biologic therapy is now an option for some patients, and what the modern combined approach can offer.
What is obstructive sleep apnea?
Plain-language primer on obstructive sleep apnea, why CPAP has been the standard, and what is changing in OSA therapy.
What is refractory chronic cough?
Plain-language primer on refractory chronic cough, why it is a distinct condition, and what is changing in therapy.
How chronic cough has emerged as a discrete indication with its own pipeline
Chronic cough was historically managed within the broader respiratory and ENT framework as a symptom rather than as an indication. The emergence of P2X3 receptor antagonists and adjacent novel mechanisms has established chronic cough as a discrete therapeutic indication with a distinct pipeline, regulatory pathway and commercial logic.